A modified Bacillus cereus phospholipase C enzyme is provided, as well as a method of using the modified phospholipase C enzyme in a method of treating vegetable oil. In certain embodiments, this method may comprise combining a vegetable oil with an modified phospholipase C enzyme comprising an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:1, wherein the amino acid residue at position 66 is a Trp (W) or Tyr (Y), and maintaining the combination under conditions suitable for the modified phospholipase C enzyme to catalyze the hydrolysis of phospholipids in the oil to produce diacylglycerol and a water soluble phosphate.
FIG. 1
The figure shows a graph comparing the chemical shifts of various compounds in crude oil and PLC BCY treated oil. The chemical shifts (in ppm) of different compounds are as follows:

<table>
<thead>
<tr>
<th>Compound</th>
<th>Chemical Shift (ppm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHOSPHOETHANOLAMINE</td>
<td>3.82</td>
</tr>
<tr>
<td>PHOSPHATIDIC ACID</td>
<td>3.706</td>
</tr>
<tr>
<td>PHOSPHOCHOLINE</td>
<td>3.25</td>
</tr>
<tr>
<td>PHOSPHATIDYLETHANOLAMINE</td>
<td>-0.1825</td>
</tr>
<tr>
<td>PHOSPHATIDYLINOSITOL</td>
<td>-0.6556</td>
</tr>
<tr>
<td>PHOSPHATIDYLCHOLINE</td>
<td>-0.809</td>
</tr>
</tbody>
</table>

FIG. 4
MODIFIED BACILLUS CEREUS  
PHOSPHOLIPASE C PROTEIN AND METHOD OF PROCESSING VEGETABLE OIL.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of International Application No. PCT/US2014/043294, filed Jun. 19, 2014, which claim priority to U.S. Provisional Application No. 61/842,880, filed on Jul. 3, 2013, which application is incorporated herein in its entirety.

BACKGROUND OF THE INVENTION

Phospholipase C catalyzes the hydrolysis of the sn-3 phosphate head group in phospholipids including phosphatidylcholine, phosphatidylethanolamine, and phosphatidylerine, resulting in the formation of 1,2-diacylglycerol and water soluble phosphate esters (e.g., phosphorycholine, phosphorylethanolamine, and phosphorylserine). Because of this activity phospholipase C can be used for refining vegetable oils such as soybean oil.

Phospholipase C can be used to process vegetable oils, e.g., vegetable oils intended for human consumption or biodiesel production such as soybean, corn, canola, rape-seed, and sunflower oil. In many cases, degumming is the first step in the refining of crude oil. In enzymatic degumming, phospholipase C is added to crude oil, and the mixture is heated in the presence of water. Under these conditions, phospholipase C hydrolyses the major oil phospholipids, e.g., phosphatidylcholine and phosphatidylethanolamine. The resulting esters, e.g., phosphorylcholine and phosphorylethanolamine, are soluble in water and separated from the oil, e.g., by centrifugation. 1,2-diacylglycerol, which is also formed during the hydrolysis, remains in the oil phase. The residual phospholipase C can be removed from the oil during subsequent purification steps, e.g., by repeatedly washing of the oil with hot water, bleaching, and decolorization.

SUMMARY OF THE INVENTION

A modified Bacillus cereus phospholipase C polypeptide is provided, as well as a method of using the polypeptide in a method of treating vegetable oil. In certain embodiments, this method may comprise combining a vegetable oil with an isolated phospholipase C enzyme comprising an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:1, wherein the amino acid residue at position 66 is a Trp (W) or Tyr (Y), and maintaining the combination under conditions suitable for the phospholipase C enzyme to catalyze the hydrolysis of phospholipids in the oil.

BRIEF DESCRIPTION OF THE DRAWINGS

Various figures are provided herewith. The skilled artisan will understand that the drawings, described below, are for illustration purposes only. The drawings are not intended to limit the scope of the present teachings in any way.

FIG. 1 shows graphs of Pichia pastoris fermentation. 1A. Growth curve. 1B. Phospholipase C activity measured with O-(4-nitrophenylphosphoryl) choline as substrate. 1C. SDS-PAGE analysis of supernatant. Samples were taken at 21, 30, 45 and 65 h.

FIG. 2 shows a graph of phospholipase C activity of PLC\textsubscript{BC} and PLC\textsubscript{BC} in aqueous media with O-(4-nitrophenylphosphoryl) choline. Phospholipase C activity of PLC\textsubscript{BC} and PLC\textsubscript{BC} were compared using 2.2 μM protein and 1 m M O-(4-nitrophenylphosphoryl) choline. OD 405 nm was monitored for 1 h at 35°C. FIG. 3 shows a graph of oil degumming by PLC\textsubscript{BC} and PLC\textsubscript{BC}. Phospholipase C activity in crude soybean oil of PLC\textsubscript{BC} and PLC\textsubscript{BC} were compared using 2.2 μM protein as described in the materials and methods section.

FIG. 4. NMR analysis of crude and PLC\textsubscript{BC} treated oil. Crude soybean oil was treated with PLC\textsubscript{BC} for 2 hrs at 35°C. Treated oil was extracted as described in methods and analyzed by NMR.

DEFINITIONS

The terms “determining”, “measuring”, “evaluating”, “assessing” and “assaying” are used interchangeably herein to refer to any form of measurement, and include determining if an element is present or not. These terms include both quantitative and/or qualitative determinations. Assessing may be relative or absolute. “Determining the presence of” includes determining the amount of something present, as well as determining whether it is present or absent.

The term “contacting” means to bring or put together. As such, a first item is contacted with a second item when the two items are brought or put together, e.g., by touching them to each other or combining them in the same solution.

The terms “protein” and “polypeptide” are used interchangeably herein.

The term “nucleic acid” encompasses DNA, RNA, single stranded or double stranded and chemical modifications thereof. The terms “nucleic acid” and “polynucleotide” are used interchangeably herein.

The term “operably-linked” refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably-linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter). “Unlinked” means that the associated genetic elements are not closely associated with one another and the function of one does not affect the other.

The term “construct” refers to any polynucleotide that contains a recombinant nucleic acid. A construct may be present in a vector (e.g., a viral vector) or may be integrated in a genome, for example.

The term “selectable marker” refers to a protein capable of expression in a host that allows for ease of selection of those hosts containing an introduced nucleic acid or vector. Examples of selectable markers include, but are not limited to, proteins that confer resistance to antimicrobial agents (e.g., hygromycin, bleomycin, or chloramphenicol), proteins that confer a metabolic advantage, such as a nutritional advantage on the host cell, as well as proteins that confer a functional or phenotypic advantage (e.g., cell division) on a cell.

The term “expression”, as used herein, refers to the process by which a polypeptide is produced based on the nucleic acid sequence of a gene. The process includes both transcription and translation.

The term “introduced” in the context of inserting a nucleic acid sequence into a cell, means “transfection”, or “transformation” or “transduction” and includes reference to the incorporation of a nucleic acid sequence into a eukaryotic or
prokaryotic cell wherein the nucleic acid sequence may be incorporated into the genome of the cell (e.g., chromosome, plasmid, plastid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (e.g., transfected mRNA).

As used herein, “expression vector” refers to a DNA construct containing a DNA sequence that is operably linked to a suitable control sequence capable of effecting the expression of the DNA in a suitable host. Such control sequences include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome binding sites and sequences which control termination of transcription and translation. The vector may be a plasmid, a phage particle, or simply a potential genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or may, in some instances, integrate into the genome itself. In the present specification, “plasmid,” “expression plasmid,” and “vector” are often used interchangeably as the plasmid is the most commonly used form of vector at present. However, the invention is intended to include such other forms of expression vectors that serve equivalent functions and which are, or become, known in the art.

As used herein, “corresponding to,” refers to a residue at the enumerated position in a protein or peptide, or a residue that is equivalent in position to the enumerated residue in a different protein or peptide. Identifying corresponding amino acids may be done by aligning the sequences and identifying residues that lie across from one another in the resultant alignment. In other words, the residue number or residue position of a given polymer is designated with respect to the reference sequence rather than by the actual numerical position of that residue within the given amino acid or polynucleotide sequence.

As used herein, “wild-type”, “native” and “naturally-occurring” refers to proteins that are those found in nature. The term “wild-type sequence,” is used herein to refer to a sequence that is native or naturally occurring in a host cell. The term “non-naturally occurring” refers to proteins that are not found in nature.

As used herein, the term “isolated” refers to a substance that has been removed from the source in which it naturally occurs. A substance need not be purified in order to be isolated. For example, a protein produced in a host cell is considered isolated when it is removed or released from the cell. A protein contained within a crude cell lysate fraction is considered “isolated” for purposes of the present disclosure.

As used herein, the term “purified” refers to a substance that has been rendered at least partially free of contaminants and other materials that typically accompany it. Substances can be purified to varying degrees. A substance is “substantially pure” when a preparation or composition of the substance contains less than about 1% contaminants. A substance is “essentially pure” when a preparation or composition of the substance contains less than about 5% contaminants. A substance is “pure” when a preparation or composition of the substance contains less than about 2% contaminants. For substances that are “purified to homogeneity,” contaminants cannot be detected with conventional analytical methods. The term “recombinant” refers to a polynucleotide or polypeptide that does not naturally occur in a host cell. A recombinant molecule may contain two or more naturally-occurring sequences that are linked together in a way that does not occur naturally. A recombinant cell contains a recombinant polynucleotide or polypeptide.

The term “heterologous” refers to elements that are not normally associated with each other. For example, if a host cell produces a heterologous protein, that protein that is not normally produced in that host cell. Likewise, a promoter that is operably linked to a heterologous coding sequence is a promoter that is operably linked to a coding sequence that it is not usually operably linked to in a wild-type host cell. The term “homologous”, with reference to a polynucleotide or protein, refers to a polynucleotide or protein that occurs naturally in a host cell.

As used herein, the terms “percent sequence identity,” “percent identity,” and/or “percent identical” are used herein to refer to comparisons between polynucleotide sequences or polypeptide sequences, and are determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) to the reference sequence in order to effect optimal alignment. The percentage identity is calculated by dividing the number of matched portions in the comparison window by the total number of positions in the comparison window, and multiplying by 100. The number of matched positions in the comparison window is the sum of the number of positions of the comparison polynucleotide or polypeptide in the window that are identical in sequence to the reference polynucleotide or polypeptide and the number of positions of the reference polynucleotide or polypeptide in the comparison window that align with a gap in the comparison polynucleotide or polypeptide. Determination of optimal alignment and percent sequence identity is performed using the BLAST and BLAST 2.0 algorithms (see, e.g., Altschul et al., 1990, J. Mol. Biol. 215:403-410 and Altschul et al., 1997, Nucleic Acids Res. 25(17):3389-3402). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information website.

Briefly, the BLAST analyses involve first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., 1990, supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatches without W, always <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, 1989, Proc. Nat’l Acad. Sci. USA
Numerous other algorithms are available that function similarly to BLAST in providing percentage identity between sequences.


As used herein, the term “reference sequence” refers to a specified sequence to which another sequence is compared. A reference sequence may be a subset of a larger sequence, for example, a segment of a full-length gene or polypeptide sequence. Generally, a reference sequence is at least 20 nucleotide or amino acid residues in length, at least 25 residues in length, at least 50 residues in length, or the full length of the nucleic acid or polypeptide. Since two polynucleotides or polypeptides may each (1) comprise a sequence (i.e., a portion of the complete sequence) that is similar between the two sequences, and (2) may further comprise a sequence that is divergent between the two sequences, sequence comparisons between two (or more) polynucleotides or polypeptide are typically performed by comparing sequences of the two polynucleotides over a comparison window to identify and compare local regions of sequence similarity. The term “reference sequence” is not intended to be limited to wild-type sequences, and can include engineered, variant and/or altered sequences.

As used herein, the term “comparison window” refers to a conceptual segment of at least about 20 contiguous nucleotide positions or amino acid residues wherein a sequence may be compared to a reference sequence of at least 20 contiguous nucleotides or amino acids and wherein the portion of the sequence in the comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The comparison window can be longer than 20 contiguous residues, and includes, optionally 30, 40, 50, 100, or longer windows.

As used herein, the term “amino acid substitution” refers to the replacement of a first amino acid with any other amino acid.

A “conservative” amino acid substitution is a substitution of an amino acid from the same group, where the groups are defined as follows: group 1: gly, ala; group 2: val, ile, leu; group 3: asp, glu; group 4: asn, gln; group 5: ser, thr; group 6: lys, arg; and group 7: phe, tyr.

The term “phospholipase” refers to an enzyme having any phospholipase activity, for example, cleaving a glycerol-phosphate ester linkage (catalyzing hydrolysis of a glycerophosphate ester linkage), e.g., in an oil, such as a vegetable oil. A phospholipase activity can generate a water extractable phosphorylated base and a diglyceride. A phospholipase activity also includes hydrolysis of glycerophosphate ester linkages at high temperatures, low temperatures, alkaline pHs and at acidic pHs. The term “a phospholipase activity” also includes cleaving a glycerophosphate ester to generate a water extractable phosphorylated base and a diglyceride. The term “a phospholipase activity” also includes cutting ester bonds of glycerin and phosphoric acid in phospholipids. The phospholipase activity can comprise a phospholipase C (PLC) activity; a phospholipase A (PLA) activity, such as a phospholipase A1 or phospholipase A2 activity; a phospholipase B (PLB) activity, including lysophospholipase (LPL) activity and/or lysophospholipase-transacetylase (LPTA) activity; a phospholipase D (PLD) activity; and/or a putatin activity or any combination thereof. An enzyme that has phospholipase activity may have other catalytic activities in addition to a phospholipase activity.

The term “vegetable oil” refers to any oil that can be processed from a vegetable, particularly an oil that can be processed for human or animal consumption such as rice bran oil, palm oil, rapeseed oil, corn oil, soybean oil, canola oil, sesame oil, peanut oil or sunflower oil. This term includes raw oil as well as partially processed versions of the same.

For clarity and unless otherwise indicated, all enumerated amino acid positions in this disclosure are with reference to the following PLC sequence (from Bacillus cereus; the secreted form of the protein of Genbank Accession No. GI:218233076): WSAEDHKEGVSNSLWTVINRDIM-SRNTTLVOKQRVALLNEWRELENGYADYENPYYDNSTFASHFYDPDNGTKYPIYAKAQETGAKYFKLAGEYSYKNKDMKQAGFFYGLSLHYLGDVPNQPM-HAANFTLNSYPQQFIHSHKYNENFDIATKDNYKVT-DGNYYWNWKGITNPEDWIIHGAABVAKQDYAGIVNDTNDWFEVRAXAQSEY-ADKWRAEVTPMGTKLMAQRVTAGYIQIWFED-TYGNR (SEQ ID NO:1). If a protein is indicated as having a substitution, the protein has a substitution at the position that corresponds to the indicated position. For example, if a protein is described as having the following amino acid substitutions F66W or F66Y or “wherein the amino acid residue at position 66 is a Trp (W) or a Tyr (Y)”, the protein will have a tryptophan residue or a tyrosine residue at the position that corresponds to position 66 in SEQ ID NO:1.

Other definitions of terms may appear throughout the specification.

DESCRIPTION OF EXEMPLARY EMBODIMENTS

Before the present subject invention is described further, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All pharmaceuticals mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.
It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, reference to “a cell” includes a plurality of cells and reference to “a candidate agent” includes reference to one or more candidate agents and equivalents thereof known to those skilled in the art, and so forth. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely”, “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.

The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.

A method for treating a vegetable oil is provided. In certain embodiments, this method may comprise combining vegetable oil with an isolated phospholipase C enzyme comprising an amino acid sequence that is at least 85% identical (e.g., at least 90% identical, at least 95% identical, at least 98% identical, at least 99% or 100% identical) to the amino acid sequence of SEQ ID NO:1, except that the amino acid residue at position 66 (underlined in the following sequence ENPYYDNSTASHYDPDNG (SEQ ID NO:7)) is a Trp (W) or Tyr (Y). Optionally, the amino acid residues at positions 63, 131 and 134 are not Asn (N). For example, in one embodiment, the amino acid residues at positions 63 is an Asp (D), the amino acid residue at position 131 is a Ser (S) and the amino acid residue at position 134 is an Asp (D). The resultant combination is maintained under conditions suitable for the phospholipase C activity of the enzyme to catalyze the hydrolysis of phospholipids in the oil to produce a water soluble phosphate ester. Depending on whether other enzymes are included, the reaction may also produce diacylglycerol, monoacylglycerol or glycerol. In many cases, the reaction results in 1,2-diacylglycerol and a water soluble phosphate ester. The vegetable oil can be from any suitable plant, including soybeans, rapeseed, sunflower seeds, rice bran oil, sesame or peanuts, for example. In some cases (and depending on the oil and other enzymes used), phosphatidylycholine and/or phosphatidylethanolamine may be hydrolyzed to produce diacylglycerol and water-soluble phosphate esters of choline and ethanolamine, respectively.

In some cases, the method may comprise contacting the vegetable oil with the phospholipase C enzyme, and incubating the mixture to a temperature of at least 40°C in the optional presence of, e.g., 0.5%–5% (v/v) water. In some embodiments, the method may further comprise separating the water-soluble phosphate esters from the diacylglycerol. This may be done by centrifugation, although other separation methods may be used.

In particular embodiments, the polypeptide may be combined with the vegetable oil at a ratio in the range of 100 to 1000 grams (e.g., 200 to 800 grams) of protein per metric ton of oil.

Also provided herein is a composition of matter comprising a vegetable oil and an isolated phospholipase C enzyme comprising the amino acid sequence that is at least 85% identical (e.g., at least 90% identical, at least 95% identical, at least 98% identical, at least 99% or 100% identical) to the amino acid sequence of SEQ ID NO:1, wherein the amino acid residue at position 66 is a Trp (W) or Tyr (Y). Optionally, the amino acid residues at positions 63, 131 and 134 are not Asn (N), e.g., the amino acid residues at positions 63 is an Asp (D), the amino acid residue at position 131 is a Ser (S) and the amino acid residue at position 134 is an Asp (D), as described above. In certain embodiments, the vegetable oil is soybean oil, rapeseed oil, sunflower oil, rice bran oil, sesame or peanuts, for example. In certain cases, the composition comprises up to 10% water (v/v), e.g., (up to 5% water, up to 4% water, up to 3% water, up to 2% water or up to 1% water or less than 0.05% water) and may be at an elevated temperature, e.g., a temperature of at least 40°C, e.g., a temperature in the range of 45°C to 80°C. In particular embodiments, the protein may be thermostable in that it, e.g., retains at least 90% of its phospholipase activity when its temperature is raised from 37°C to a selected temperature in the range of 45°C to 80°C. Also provided herein is an isolated phospholipase C enzyme comprising the amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:1, wherein the amino acid residue at position 66 is a Trp (W) or Tyr (Y) and the amino acid residues at positions 63, 131 and 134 are not Asn (N). In some embodiments, the amino acid residues at positions 63, 131 and 134 are independently selected from a Ser (S) and an Asp (D). For example, in one embodiment, the amino acid residues at positions 63 is an Asp (D), the amino acid residue at position 131 is a Ser (S) and the amino acid residue at position 134 is an Asp (D). In particular embodiments, the amino acid sequence of the isolated polypeptide comprises the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:5. In any embodiment, the amino acid residue at position 134 of the isolated phospholipase C enzyme is an Ala (A).

In any embodiment, the isolated phospholipase C enzyme may have the amino acid sequence of SEQ ID NO:5, with the exception of the following amino acid substitutions: Q139W, D63M, D63F or D63W.

In any embodiment, the isolated phospholipase C enzyme may have the amino acid sequence of SEQ ID NO:5, with the exception of the following amino acid substitution: Y56T.

A nucleic acid encoding the isolated phospholipase C enzyme is also provided. In certain embodiments, the nucleotide sequence of the nucleic acid is set forth in SEQ ID NO:2, wherein the codon defined by positions 196–198 is a TGG or TAC. A cell comprising this nucleic acid is also
provided. In certain cases, the cell is a *Pichia pastoris* cell and the nucleotide sequence of the nucleic acid is set forth in SEQ ID NO:2, wherein the codon defined by positions 196-198 is a TGG or TAC. Such a cell may be used to make the above-described polypeptide. In one embodiment, this method may comprise incubating cells containing the nucleic acid, and harvesting the phospholipase C from the culture medium.

Phospholipases are enzymes that hydrolyze the ester bonds of phospholipids. Several types of phospholipases are known which differ in their specificity according to the position of the bond attacked in the phospholipid molecule. Phospholipase A1 (PLA1) removes the 1-position fatty acid to produce free fatty acid and 1-lyso-2-acylphospholipid. Phospholipase A2 (PLA2) removes the 2-position fatty acid to produce free fatty acid and 1-acyl-2-lysophospholipid. PLA1 and PLA2 enzymes can be intra- or extra-cellular, membrane-bound or soluble. Intracellular PLA2 is found in almost every mammalian cell. Phospholipase C (PLC) removes the phosphate moiety to produce 1,2 diacylglycerol and phosphate ester. Phospholipase D (PLD) produces 1,2-diacylglycerophosphate and base group. PLC and PLD are important in cell function and signaling. PLD had been the dominant phospholipase in biocatalysis (see, e.g., Godfrey, T. and West S. (1996) Industrial enzymology, 299-300, Stockton Press, New York). Patatin is another type of phospholipase, thought to work as a PLA (see for example, Hirschberg H J, et al., (2001), Eur J Biochem 268(10):5037-44).

Common oilseeds, such as soybeans, rapeseed, sunflower seeds, rice bran oil, sesame and peanuts are used as sources of oils and feedstock. In the oil extraction process, the seeds are mechanically and thermally treated. The oil is separated and divided from the meal by a solvent. Using distillation, the solvent is then separated from the oil and the oil is recovered. The oil is “degummed” and refined. The solvent content in the meal can be evaporated by thermal treatment, followed by meal drying and cooling. After a solvent had been separated by distillation, the produced raw oil can be processed using special degumming procedures and physical refining. The oil can also be utilized as feedstock for the production of fatty acids and methyl ester. The meal can be used for animal food.

Degumming is usually the first step in vegetable oil refining and it is designed to remove contaminating phosphatides that are extracted with the oil but interfere with the subsequent oil processing. These phosphatides are soluble in the vegetable oil only in an anhydrous form and can be precipitated and removed if they are hydrated. Hydration may be accomplished by mixing a small proportion of water with substantially dry oil in the presence of phospholipase C enzyme. The temperature of the reaction is not highly critical, although separation of the hydrated gums is more efficient when the viscosity of the oil is reduced at 50°C to 80°C.


In one aspect, a nucleic acid encoding a subject phospholipase C enzyme is assembled in appropriate phase with a leader sequence capable of directing secretion of the translated polypeptide or fragment thereof.

In certain embodiments, the polypeptide can be fused to a heterologous peptide or polypeptide, such as N-terminal identification peptides which impart desired characteristics, such as increased stability or simplified purification. Peptides and polypeptides of the invention can also be synthesized and expressed as fusion proteins with one or more additional domains linked thereto for, e.g., producing a more immunogenic peptide, to more readily isolate a recombinantly synthesized peptide. Detection and purification facilitating domains include, e.g., metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGs extension/affinity purification system (Immunex Corp, Seattle Wash.). The inclusion of a cleavable linker sequences such as Factor Xa or enterokinase (Invitrogen, San Diego Calif.) between a purification domain and the motif-comprising peptide or polypeptide to facilitate purification. For example, an expression vector can include an epitope-encoding nucleic acid sequence linked to six histidine residues followed by a thioredoxin and an enterokinase cleavage site (see e.g., Williams (1995) Biochemistry 34:1787-1797; Dobeli (1998) Protein Expr. Purif. 12:404-414). The histidine residues facilitate detection and purification while the enterokinase cleavage site provides a means for purifying the epitope from the remainder of the fusion protein. Technology pertaining to vectors encoding fusion proteins and application of fusion proteins are well described in the scientific and patent literature, see e.g., Kroll (1993) DNA Cell Biol., 12:441-53.

A nucleic acid may be operatively linked to expression (e.g., transcriptional or translational) control sequence(s), e.g., promoters or enhancers, to direct or modulate RNA synthesis/expression. The expression control sequence can be in an expression vector. Exemplary bacterial promoters
include lacI, lacZ, T3, T7, gpt, lambda PR, PL and trp. Exemplary eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retroviruses, and mouse metallothionein 1.

Promoters suitable for expressing a polypeptide in bacteria include the E. coli lac or trp promoters, the lad promoter, the lacZ promoter, the T3 promoter, the T7 promoter, the gpt promoter, the lambda PR promoter, the lambda PL promoter, promoters from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), and the acid phosphatase promoter. Eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, heat shock promoters, the early and late SV40 promoter,LTRs from retroviruses, and the mouse metallothionein-1 promoter. Other promoters known to control expression of genes in prokaryotic or eukaryotic viruses may also be used.

Expression vectors are encoding a subject polypeptide are also provided. Expression vectors may comprise viral particles, baculovirus, phage, plasmids, phagemids, cosmids, fosmids, bacterial artificial chromosomes, viral DNA (e.g., vaccinia, adenovirus, fowl pox virus, pseudorabies and derivatives of SV40), Pl-based artificial chromosomes, yeast plasmids, yeast artificial chromosomes, and any other vectors specific for specific hosts of interest (such as Bacillus, Pichia, Aspergillus and yeast, etc.). Vectors include chromosomal, non-chromosomal and synthetic DNA sequences. Large numbers of suitable vectors are known to those skilled in the art, and are commercially available. Exemplary vectors include: bacterial: pQE vectors (Qiagen), pBluescript plasmids, pNH vectors, (lambda-ZAP vectors (Stratagene); ptc99a, pKK223-3, pDR540, pHT3T (Pharmacia); Eukaryotic: pXT1, pSG5 (Stratagene), pSVK3, pBPV, pMSG, pSVL40 (Pharmacia). However, any other plasmid or other vector may be used so long as they are replicable and viable in the host. Low copy number or high copy number vectors may be employed with the present invention.

An expression vector may comprise a promoter, a ribosome-binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression. Mammalian expression vectors may contain an origin of replication, any necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking non-transcribed sequences. In some aspects, DNA sequences derived from the SV40 splice and polyadenylation sites may be used to provide the required non-transcribed genetic elements.

In one aspect, the expression vector may contain one or more selectable marker genes to permit selection of host cells containing the vector. Such selectable markers include genes encoding dihydrofolate reductase or genes conferring neomycin resistance for eukaryotic cell culture, genes conferring tetracycline or ampicillin resistance in E. coli, and the S. cerevisiae TRP1 gene. Promoter regions can be selected from any desired gene using chloramphenicol transferase (CAT) vectors or other vectors with selectable markers.

A DNA sequence may be inserted into a vector by a variety of procedures. In general, the DNA sequence is ligated to the desired position in the vector following digestion of the insert and the vector with appropriate restriction endonucleases. Alternatively, blunt ends in both the insert and the vector may be ligated. A variety of cloning techniques are known in the art, e.g., as described in Ausubel and Sambrook.

Such procedures and others are deemed to be within the scope of those skilled in the art. Transformed cell comprising a nucleic acid encoding a subject polypeptide are also provided. The host cell may be any of the host cells familiar to those skilled in the art, including prokaryotic cells, eukaryotic cells, such as bacterial cells, fungal cells, yeast cells, mammalian cells, insect cells, or plant cells. Enzymes of the invention can be expressed in any host cell, e.g., any bacterial cell, any yeast cell, e.g., Pichia pastoris, Saccharomyces cerevisiae or Schizosaccharomyces pombe. Exemplary bacterial cells include E. coli, Lactococcus lactis, Streptomyces coelicolor, Bacillus subtilis, Bacillus cereus, Salmonella typhimurium or any species within the genera Bacillus, Streptomyces and Staphylococcus. Exemplary insect cells include Drosophila S2 and Spodoptera S19. Exemplary animal cells include CHO, COS or Bowes melanoma or any mouse or human cell line. The selection of an appropriate host is within the abilities of those skilled in the art.

Where appropriate, the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the invention. Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter may be induced by appropriate means (e.g., temperature shift or chemical induction) and the cells may be cultured for an additional period to allow them to produce the desired polypeptide or fragment thereof.

Cells can be harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract is retained for further purification. Microbial cells employed for expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Such methods are well known to those skilled in the art. The expressed polypeptide or fragment thereof can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the polypeptide. If desired, high performance liquid chromatography (HPLC) can be employed for final purification steps.

The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. Depending upon the host employed in a recombinant production procedure, the polypeptides produced by host cells containing the vector may be glycosylated or may be non-glycosylated. Polypeptides of the invention may or may not also include an initial methionine amino acid residue.

The subject polypeptide can be used in various vegetable oil processing steps, such as in vegetable oil extraction, particularly, in the removal of phospholipid gums in a process called "oil degumming". These processes can be used in a process scale, e.g., on a scale from about 15,000; 25,000; 50,000; 75,000; or 100,000 or more lbs of refined oil/day up to about 1, 2, 3, 4, 5 or 6 or more million lbs refined oil/day.

In one embodiment, this disclosure provides processes comprising use of a subject, enzyme to reduce gum mass and increase neutral oil (triglyceride) gain through reduced oil entrainment. In one embodiment, the process comprises use
of a subject polypeptide for increasing neutral oils and diacylglycerol (DAG) production to contribute to the oil phase. The degumming process may additionally comprise use of one or more other enzymes such as a protease, an amylase, a lipase, a cutinase, another phospholipase (including, e.g., an enzyme of the invention), a carboxydase, a cellulase, a pectinase, a mannanase, an arabinase, a galactanase, a xylanase, an oxidase, e.g., a lactase, and/or a peroxidase, or polypeptides with equivalent activity, or a combination thereof.

The subject polypeptide can be used in various vegetable oil processing steps, such as in vegetable oil extraction, particularly, in the removal of “phospholipid gums” in a process called “oil degumming,” as described above. The invention provides methods for processing vegetable oils from various sources, such as rice bran, soybeans, rapeseed, peanut, and other nuts, corn, sunflower, palm, and coconut. The methods can be used in conjunction with processes based on extraction with hexane, with subsequent refining of the crude extracts to edible oils. The first step in the refining sequence is the so-called “degumming” process, which serves to separate phosphatides by the addition of water. The material precipitated by degumming is separated and further processed to mixtures of lecithins. The commercial lecithins, such as soybean lecithin and sunflower lecithin, are semisolid or very viscous materials. They consist of a mixture of polar lipids, mainly phospholipids, and oil, mainly triglycerides.

The subject polypeptide can be used in any “degumming” procedure, including water degumming, ALCON oil degumming (e.g., for soybeans), safineco degumming, “super degumming,” UF degumming, TOP degumming, uni-degumming, dry degumming and ENZYMAX™ degumming. See, e.g., U.S. Pat. Nos. 6,535,693; 6,162,623; 6,103,505; 6,001,640; 5,558,781; 5,264,567. Various “degumming” procedures incorporated by the method of the invention are described in Bockisch, M. (1998) In Fats and Oils Handbook. The Extraction of Vegetable Oils (Chapter 5), 345-445, AOCS Press, Champaign, Ill. The phospholipases of the invention can be used in the industrial application of enzymatic degumming of triglyceride oils as described, e.g., in EP 513 709.

In one aspect, subject polypeptide is used to treat vegetable oils, e.g., crude oils, such as rice bran, soy, canola, flower and the like. In one aspect, this improves the efficiency of the degumming process. In one aspect, the invention provides methods for enzymatic degumming under conditions of low water, e.g., in the range of between about 0.1% to 20% water; or, 0.5% to 10% water. In one aspect, this results in the improved separation of a heavy phase from the oil phase during centrifugation. The improved separation of these phases can result in more efficient removal of phospholipids from the oil, including both hydratable and nonhydratable oils. In one aspect, this can produce a gum fraction that contains less entrained neutral oil (triglycerides), thereby improving the overall yield of oil during the degumming process.

In one aspect, the method may comprise hydrolysis of hydrated phospholipids in oil at a temperature of about 20°C. to 40°C., at an alkaline pH, e.g., a pH of about 8 to pH 10, using a reaction time of about 10 minutes to 10 hours, e.g., 1 hr to 5 hr. This can result in less than 10 ppm final oil phosphorus levels. In certain cases, the method may comprise hydrolysis of hydratable and non-hydratable phospholipids in oil at a temperature of about 50°C. to 60°C., at a pH slightly below neutral, e.g., of about pH 5 to pH 6,

using a reaction time of, 10 minutes to 10 hours, e.g., 1 hr to 5 hr. This can result in less than 10 ppm final oil phosphorus levels.

In one aspect, the subject polypeptide may be used to hydrolyze a glycerylphosphoester bond and thereby enable the removal of the diacylglyceride portion of phospholipids back to the oil, e.g., a vegetable, fish or algae oil; and, reduce the phospholipid content in a degumming step to levels low enough for high phosphorus oils to be physically refined. The two approaches can generate different values and have different target applications.

In one exemplary process, when the enzyme is added to and reacted with a crude oil, the amount of phospholipase employed is about 10-10,000 units, or, alternatively, about 100-2,000 units, per 1 kg of crude oil. The enzyme treatment may be conducted for 5 min to 10 hours at a temperature of 30°C. to 90°C., or, alternatively, about 40°C. to 70°C. The conditions may vary depending on the optimum temperature of the enzyme. The amount of water added may be 0.1-20 wt. parts per 100 wt. parts of crude oil. In some cases, the final mixture may be composed of 1% to 10%, water, e.g., 2-4% water.

Upon completion of such enzyme treatment, the liquid may be separated with an appropriate means such as a centrifugal separator and the processed oil is obtained. Phosphorus-containing compounds produced by enzyme decomposition of gummy substances in such a process are practically all transferred into the aqueous phase and removed from the oil phase. Upon completion of the enzyme treatment, if necessary, the processed oil can be additionally washed with water or organic or inorganic acid such as, e.g., acetic acid, citric acid, phosphoric acid, succinic acid, and equivalent acids, or with salt solutions.

In one exemplary process for ultra-filtration degumming, the enzyme is bound to a filter or the enzyme is added to an oil prior to filtration or the enzyme is used to periodically clean filters.

In one exemplary process for a phospholipase-mediated physical refining aid, water and enzyme are added to crude oil (e.g., crude vegetable oil). In one aspect, a subject polypeptide and a phosphatase are used in the process. In phospholipase-mediated physical refining, the water level can be low, i.e. 0.5-5% and the process time should be short (less than 2 hours, or, less than 60 minutes, or, less than 30 minutes, or, less than 15 minutes, or, less than 5 minutes). The process can be run at different temperatures (25°C. to 70°C.), using different acids and/or caustics, at different pHs (e.g., 3-10).

In alternate aspects, water degumming is performed first to collect lecithin by centrifugation and then a subject polypeptide is added to remove non-hydratable phospholipids (the process should be performed under low water concentration). In another aspect, water degumming of crude oil to less than 10 ppm (edible oils) and subsequent physical refining (less than 50 ppm for biodiesel) is performed. In one aspect, an emulsifier is added and/or the crude oil is subjected to an intense mixer to promote mixing. Alternatively, an emulsion-breaker is added and/or the crude oil is heated to promote separation of the aqueous phase. In another aspect, an acid is added to promote hydration of non-hydratable phospholipids. Additionally, phospholipases can be used to mediate purification of phytoesters from the gum-soapstock.

In certain cases, a subject polypeptide and at least one plant wall degrading agent (e.g., a cellulase, a hemicellulase or the like, to soften walls and increase yield at extraction) can be used. In this exemplary approach to using enzymes of the
invention to improve oil extraction and oil degumming, subject polypeptide as well as other hydrolyses (e.g., a cellulase, a hemicellulase, an esterase, a protease and/or a phosphatase) are used during the crushing steps associated with oil production (including but not limited to soybean, canola, sunflower; rice bran oil). By using enzymes prior to or in place of solvent extraction, it is possible to increase oil yield and reduce the amount of hydratable and non-hydratable phospholipids in the crude oil. The reduction in non-hydratable phospholipids may result from conversion of potentially non-hydratable phospholipids to diacylglycerol and corresponding phosphate-ester prior to complexation with calcium or magnesium. The overall reduction of phospholipids in the crude oil will result in improved yields during refining with the potential for eliminating the requirement for a separate degumming step prior to bleaching and deodorization.

In one aspect, to allow the enzyme of the invention to act, both phases, the oil phase and the aqueous phase that contain the enzyme, must be intimately mixed. It may not be sufficient to merely stir them. Good dispersion of the enzyme in the oil is aided if it is dissolved in a small amount of water, e.g., 0.5-5 weight-% (relative to the oil), and emulsified in the oil in this form, to form droplets of less than 10 micrometers in diameter (weight average). The droplets can be smaller than 1 micrometer. Turbulent stirring can be done with radial velocities above 100 cm/s. The oil also can be circulated in the reactor using an external rotary pump. The aqueous phase containing the enzyme can also be finely dispersed by means of ultrasound action. A dispersion apparatus can be used.

The enzymatic reaction may take place at the border surface between the oil phase and the aqueous phase and, as such, the addition of surfactants may increase the microdispersion of the aqueous phase. In some cases, therefore, surfactants having HLB values above 9, such as Na-dodecyl sulfate, are added to the enzyme solution, as described, e.g., in EP-A-0 513 709. A similar effective method for improving emulsification is the addition of lysolecinithin. The amounts added can lie in the range of 0.001% to 1%, with reference to the oil. The temperature during enzyme treatment is not critical. Temperatures between 20°C and 80°C, e.g., 30°C and 50°C, can be used, but the latter can only be applied for a short time. The treatment period depends on the temperature and can be kept shorter with an increasing temperature. Times of 0.1 to 10 hours, or 1 to 5 hours may be sufficient. In certain cases, the reaction may take place in a degumming reactor, which can be divided into stages, as described, e.g., in DE-A-43 39 556. Therefore continuous operation is possible, along with batch operation. The reaction can be carried out in different temperature stages. For example, incubation can take place for 3 hours at 40°C, then for 1 hour at 60°C. If the reaction proceeds in stages, this also opens up the possibility of adjusting different PH values in the individual stages. For example, in the first stage the pH of the solution can be adjusted to 7, for example, and in a second stage to 2.5, by adding citric acid. In at least one stage, however, the pH of the enzyme solution must be below 4, or, below 3. If the pH was subsequently adjusted below this level, a deterioration of effect may be found. Therefore the citric acid can be added to the enzyme solution before the latter is mixed into the oil.

After completion of the enzyme treatment, the enzyme solution, together with the decomposition products, can be separated from the oil phase, in batches or continuously, e.g., by means of centrifugation. Since the enzymes are characterized by a high level of stability and the amount of the decomposition products contained in the solution is slight (they may precipitate as sludge) the same aqueous enzyme phase can be used several times. There is also the possibility of freeing the enzyme of the sludge, sec, e.g., DE-A 43 39 556, so that an enzyme solution which is essentially free of sludge can be used again. In one aspect of this degumming process, oils which contain less than 15 ppm phosphorus are obtained. One goal is phosphorus contents of less than 10 ppm or, less than 5 ppm. With phosphorus contents below 10 ppm or below 5 ppm, further processing of the oil according to the process of distillative de-acidification is easily possible. A number of other ions, such as magnesium, calcium, zinc, as well as iron, can be removed from the oil, e.g., below 0.1 ppm. Thus, this product possesses ideal prerequisites for good oxidation resistance during further processing and storage. In certain cases, an oil degumming process may produce a product that contains 50-70 ppm phosphate.

**EXAMPLES**

The following examples are provided in order to demonstrate and further illustrate certain embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.

In the following description, PLC<sub>B</sub>C<sub>2</sub> corresponds to protein SEQ ID NO:6, PLC<sub>B</sub>C<sub>3</sub> corresponds to SEQ ID NO:3 and PLC<sub>B</sub>C<sub>5</sub>y corresponds to SEQ ID NO:5. SEQ ID NO:2 is codon optimized PLC<sub>B</sub>C<sub>2</sub> and SEQ ID NO:4 is codon optimized PLC<sub>B</sub>C<sub>5</sub>y.

**Gene Design and Synthesis**

Protein sequences were reverse translated and codon optimized using a codon randomization method (Menzella Microbial Cell Factories 2011 10:15). Briefly, the method consists on randomly assigning a triplet for each amino acid using a preference table for *Pichia pastoris* available at the kazusa.or.jp website, with a probability based on the weight of each codon within the set encoding a given amino acid. The designed genes were synthesized by Genescript (NJ, USA).

**Plasmid and Strain Construction**

The PLC codon optimized sequences were synthesized with Xhol-Xbal restriction sites at the borders and cloned into identical sites of the pJ912 vector (DNA2.0). The resulting plasmids were linearized with ScaI and transformed by electroporation into *Pichia pastoris* cells. Transformants were selected on YPD supplemented with zeocin 100 µg/ml, 100 colonies were streaked on PLC activity plates (YP 5% egg yolk, 0.5% methanol, 1 mM ZnSO<sub>4</sub>, 1.5% agar) and colonies displaying the largest halos were selected for further analysis.

**High Cell Density *Pichia pastoris* Fermentation**

Fermentation of *Pichia pastoris* strain expressing the corresponding enzymes was performed according to the INVitrogen protocol for mut<sup>+</sup> strains. The culture medium used is 1 L of Fermentation Basal Salts Medium (BSM) pH 5 and cultures were grown at 30°C in an Infors LabFors 4 bioreactor with 2 L of working volume.

The process starts with a 16 h batch phase followed by 3 h of fed batch where the feeding rate is 18.12 mL/h of glycerol 50% WN+1.2% *Pichia* trace metals (PTM1). Next, a methanol feeding phase of 40 h induces the expression of the enzymes. The feeding rates (methanol 100%+1.2% PTM1) in the induction phase is 3.6 mL/h for the first 2 h, 7.6 mL/h for 2 additional hours and 10.9 mL/h until the end of the process. The typical process yield is 5 g/L of
secreted protein, a final OD₆₅₀ of 600, and an overall PLC volumetric productivity of 3100 Units/L·h (FIG. 1A-C).

PLC Activity Using O-(4-Nitrophenyl)phosphorylcholine Substrate

To determine PLC activity in the fermentation supernatant, 10 µl of 1/10 dilution of supernatant from Pichia pastoris cultures were incubated with 10 mM O-(4-Nitrophenyl)phosphorylcholine (OPDC) in a substrate as a buffer in 250 mM HEPES pH 7.2, 0.1 mM ZnCl₂ in a final volume of 100 µl at 35°C for 30 min. Absorbance at 405 nm was determined and PLC activity calculated. 1 PLC unit corresponds to the amount of enzyme releasing 1 µmol of p-nitrophenol per minute.

Kinetic Comparison of PLC₅₅, PLC₅₅₇, and PLC₅₅₈ with O-(4-Nitrophenyl)phosphorylcholine as a Substrate

PLC activity was measured in 96 well microplates using 1 mM O-(4-Nitrophenyl)phosphorylcholine as a substrate and 2.2 µM of each PLC in buffer 250 mM HEPES pH 7, 60% sorbitol, 0.1 mM ZnCl₂. Absorbance at 405 nm was monitored for 1 h at 50°C. The obtained data were fitted to the integrated Michaelis-Menten rate equation to obtain the corresponding curves to determine Vₘₐₓ/Kₘₐₓ (FIG. 2).

To determine Vₘₐₓ and Kₘₐₓ, PLC activity was measured using an enzyme concentration of 1.2 mM. Different substrate solutions (50, 20, 10, 5, 2, 1, 0.5, 1, and 0.1 mM) prepared in buffer 250 mM HEPES pH 7, 60% sorbitol, 0.1 mM ZnCl₂ were used and absorbance at 405 nm was monitored for 1 h at 50°C. V₀ was determined for each substrate concentration and Vₘₐₓ and Kₘₐₓ were estimated from a V₀ vs [S] curve. As shown in Table 1, the mutant enzymes showed a significant increase in the Kₘₐₓ/Kₘₐₓ parameter, being the PLC₅₅₇ enzyme the best catalytic efficiency.

**TABLE 1**

<table>
<thead>
<tr>
<th>Kinetic parameters of PLC₅₅, PLC₅₅₇, PLC₅₅₈ with O-(4- Nitrophenyl)phosphorylcholine in aqueous media.</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLC₅₅</td>
</tr>
<tr>
<td>------------------</td>
</tr>
<tr>
<td>Kₘₐₓ (mM)</td>
</tr>
<tr>
<td>kₘₐₓ (s⁻¹)</td>
</tr>
<tr>
<td>kₘₐₓ/Kₘₐₓ (s⁻¹ M⁻¹)</td>
</tr>
</tbody>
</table>

Kinetic Comparison of PLC₅₅, PLC₅₅₇, and PLC₅₅₈ in Oil

In order to compare the activity of wild type and mutant enzymes in oil, 3 ml of crude soybean oil containing 1000 ppm phospholipase was homogenized (1 min using Ultra-Turrax T8 Homogenizer, IKA) with 22.5 µg of PLC in 50 µl of buffer 10 mg/L (4-ME15 mM HEPES, 1 mM EDTA, 10% glycerol). Each tube was incubated at 55°C with constant agitation (VP 710 magnetic tumble stirrer, VP-Scientific). At different time points (5-10-20-40-60120 min) the oil was homogenized and 200 µl of the homogenized oil were mixed with 200 µl of 2M Tris-HCl pH 8 to stop the PLC reaction. Then, 800 µl of water was added, incubated for 1 h at 37°C with constant agitation and centrifuged 5 min at 14000 g. 45 µl of the aqueous phase were recovered and treated with 0.3 U of calf intestinal phosphatase (Promega, Wis., USA) for 1 h at 37°C following the manufacturer instructions. Finally, inorganic phosphate was determined according to the method of Sumner (Sumner, J. B., Science 1944 196: 413). Briefly, a 500 µl sample, containing 0.025 to 0.25 µmol of inorganic phosphate in 5% TCA was mixed with 500 µl of color reagent (4% FeSO₄, 1% (NH₄)₂MoO₄, 1.2% H₂SO₄). Spectrophotometric readings were made at 700 nm, and the micromoles of inorganic phosphate in the sample were calculated from a standard curve.

The results shown in FIG. 3 and Table 2 demonstrate that both mutant enzymes display a higher activity in oil than that of the wild type. Surprisingly and differing to the data obtained in aqueous environment, the PLC₅₅₇ enzyme shows superior catalytic properties in oil, indicating that the activity in aqueous environment cannot predict the efficiency of the mutant enzymes for the enzymatic degumming of oils.

**TABLE 2**

<table>
<thead>
<tr>
<th>Kinetic parameters of PLC₅₅, PLC₅₅₇, PLC₅₅₈ in crude oil</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLC₅₅</td>
</tr>
<tr>
<td>------------------</td>
</tr>
<tr>
<td>kₘₐₓ/Kₘₐₓ (s⁻¹ M⁻¹)</td>
</tr>
</tbody>
</table>

Enzymatic Oil Degumming

Oil degumming experiments were performed using 200 g of crude soybean oil (1000 ppm phospholipase), 3% H₂O and 2.16 mg of the different PLCs obtained. The oil was emulsified with water using an Ultra-Turrax T50 Homogenizer (IKA) for 1 min, and the containers incubated with continuous stirring with a magnetic stirrer at 55°C for 2 h. Finally, the enzyme was heat-inactivated at 85°C for 20 min and the oil centrifuged at 3000 g for 10 min to remove the remaining gums.1,2-diacylglycerol (1,2 DAG) content determination was performed according to AOCS Cd 11d-96: 2009. The results shown in Table 3 demonstrate the superior efficiency of the mutant enzymes for the oil degumming process. As expected from the kinetic analysis of the mutant enzymes in oil, the PLC₅₅₇ enzyme exhibits the highest catalytic efficiency.

**TABLE 3**

<table>
<thead>
<tr>
<th>Oil degumming using PLC₅₅, PLC₅₅₇, PLC₅₅₈</th>
<th>1,2 DAG (%)</th>
<th>1,2,3DAG (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>water</td>
<td>0.35</td>
<td>0</td>
</tr>
<tr>
<td>PLC₅₅</td>
<td>1.14</td>
<td>0.79</td>
</tr>
<tr>
<td>PLC₅₅₇</td>
<td>1.4</td>
<td>1.05</td>
</tr>
<tr>
<td>PLC₅₅₈</td>
<td>1.53</td>
<td>1.18</td>
</tr>
</tbody>
</table>

PLC₅₅₇ is protein SEQ ID NO: 5 with amino acid 134 changed to Ala. Oil degumming experiment was performed with PLC₅₅₇ and PLC₅₅₇ 134A and samples were taken at different time points and analyzed for 1,2 DAG content. We found a significant improvement in kinetic parameters when this amino acid is specifically changed to Ala.

**TABLE 4**

<table>
<thead>
<tr>
<th>Oil degumming using PLC₅₅₇ and PLC₅₅₇ 134A</th>
<th>1,2,3DAG (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>0.83</td>
</tr>
<tr>
<td>40</td>
<td>0.91</td>
</tr>
<tr>
<td>60</td>
<td>1.01</td>
</tr>
<tr>
<td>140</td>
<td>1.21</td>
</tr>
</tbody>
</table>

NMR Analysis of Crude and PLC₅₅₇ Treated Oil

Oil degumming experiments were performed as described above using PLC₅₅₇ for 2 hs at 55°C. Treated oil was
emulsified using a Ultra-Turrax T 50 Homogenizer (IKA) for 1 min before taking 300 mg samples for further analysis. Oil samples were extracted with 900 μl of NMR solution (100 mM Tris-HCl pH 10.5, 50 mM EDTA, 2.5% sodium deoxycholate) during 1 h at 37° C. with constant agitation. Finally the resulting aqueous phase was extracted with 600 μl hexane and analyzed by NMR. NMR spectra were acquired using a Bruker DRX 600 equipment and samples of phosphatidylethanolamine, phosphatidylethanolamine, phosphatidic acid and phosphatidylinositol were run as standards.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 7
<210> SEQ ID NO 1
<211> LENGTH: 245
<212> TYPE: PRT
<213> ORGANISM: Bacillus cereus

<400> SEQUENCE: 1

Trp Ser Ala Glu Asp His Lys Gly Val Asn Ser His Leu Trp
1  5  10  15
Ile Val Asn Arg Ala Ile Asp Ile Met Ser Arg Asn Thr Thr Leu Val
20  25  30
Lys Gln Asp Arg Val Ala Leu Asn Glu Trp Arg Thr Glu Leu Gln
35  40  45
Asn Gly Ile Tyr Ala Ala Asp Tyr Glu Asn Pro Tyr Tyr Asp Asn Ser
50  55  60
Thr Phe Ala Ser His Phe Tyr Asp Pro Asp Asn Gly Lys Thr Tyr Ile
65  70  75  80
Pro Tyr Ala Lys Gln Ala Lys Glu Thr Gly Ala Lys Tyr Phe Lys Leu
85  90  95
Ala Gly Glu Ser Tyr Lys Asn Asp Met Lys Glu Ala Phe Phe Tyr
100 105 110
Leu Gly Leu Ser Leu His Tyr Leu Gly Asp Val Asn Glu Pro Met His
115 120 125
Ala Ala Asn Phe Thr Asn Leu Ser Tyr Pro Glu Gly Phe His Ser Lys
130 135 140
Tyr Glu Asp Phe Val Asp Thr Ile Lys Asp Asn Tyr Lys Val Thr Asp
145 150 155 160
Gly Asn Gly Tyr Trp Asn Trp Lys Gly Thr Asn Pro Glu Asp Trp Ile
165 170 175
His Gly Ala Ala Val Ala Lys Glu Asp Tyr Ala Gly Ile Val Asn
180 185 190
Asp Asn Thr Lys Asp Trp Phe Val Arg Ala Ala Val Ser Gin Glu Tyr
195 200 205
Ala Asp Lys Trp Arg Ala Glu Val Thr Pro Met Thr Gly Lys Arg Leu
210 215 220
Met Asp Ala Gin Arg Val Thr Ala Gly Tyr Ile Gin Leu Trp Phe Asp
225 230 235 240
Thr Tyr Gly Asn Arg
245

<210> SEQ ID NO 2
<211> LENGTH: 378
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic polynucleotide

<400> SEQUENCE: 2

tggtccgcag aagcawesomea taaggaagct gtgaatatgcc attttgtgtgat tgtgaaccgt 60
gccattgaca tcagtccccc gtaattaccac ctgttttaaac aagatcgcgt ggccccgttta 120
<210> SEQ ID NO 3
<211> LENGTH: 245
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Engineered PLC

<400> SEQUENCE: 3

Try Thr Ser Ala Glu Asp Lys His Lys Gly Val Asn Ser His Leu Try
Ile Val Asn Arg Ala Ile Asp Ile Met Ser Arg Asn Thr Thr Leu Val
Lys Gln Asp Arg Val Ala Leu Leu Asn Gly Thr Arg Thr Gly Leu Glu
Asn Gly Ile Tyr Ala Ala Asp Tyr Glu Asn Pro Tyr Tyr Asp Asp Ser
Thr Trp Ala Ser His Phe Tyr Asp Pro Asp Asn Gly Lys Thr Tyr Ile
Pro Tyr Ala Lys Gln Ala Lys Glu Thr Gly Ala Lys Tyr Phe Lys Leu
Ala Gly Glu Ser Tyr Lys Asn Lys Asp Met Lys Gln Ala Phe Phe Tyr
Leu Gly Leu Ser Leu His Tyr Leu Gly Asp Val Asn Gln Pro Met His
Leu Ala Ser Phe Thr Asp Leu Ser Tyr Pro Gln Gly Phe His Ser Lys
Tyr Glu Asn Phe Val Asp Thr Ile Lys Asp Asn Tyr Lys Val Thr Asp
Gly Asn Gly Tyr Thr Asn Thr Lys Glu Thr Asp Pro Glu Asp Thr Lys
His Gly Ala Ala Val Ala Lys Gln Asp Tyr Ala Gly Ile Val Asn
Asp Asn Thr Lys Asp Thr Phe Val Arg Ala Ala Val Ser Gln Glu Tyr
Ala Asp Lys Thr Arg Ala Glu Val Thr Pro Met Thr Gly Lys Arg Leu
Met Asp Ala Gln Arg Val Thr Ala Gly Tyr Ile Gln Leu Thr Phe Asp
Thr Tyr Gly Asn Arg
<table>
<thead>
<tr>
<th>SEQ ID NO</th>
<th>LENGTH</th>
<th>TYPE</th>
<th>ORGANISM</th>
<th>FEATUR</th>
<th>OTHER INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>60</td>
<td>DNA</td>
<td>Artificial</td>
<td></td>
<td>Synthetic polynucleotide</td>
</tr>
<tr>
<td>5</td>
<td>120</td>
<td>PRT</td>
<td>Artificial</td>
<td></td>
<td>Engineered PLC</td>
</tr>
</tbody>
</table>

**Sequence 4**

tggctcgcag aagacaaaca taaaggaagct gtaaatagcc aattgtggat tgtgaacgct

ggcatggaca tcaagtcccg taataccacg ctggtaaaac aagatcgccgt ggcctgtta

**Sequence 5**

<table>
<thead>
<tr>
<th>Residue</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trp</td>
<td>Ser</td>
</tr>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Ile</td>
<td>Val</td>
</tr>
<tr>
<td></td>
<td>20</td>
</tr>
<tr>
<td>Lys</td>
<td>Gln</td>
</tr>
<tr>
<td></td>
<td>35</td>
</tr>
<tr>
<td>Asn</td>
<td>Gly</td>
</tr>
<tr>
<td></td>
<td>50</td>
</tr>
<tr>
<td>Thr</td>
<td>Tyr</td>
</tr>
<tr>
<td></td>
<td>60</td>
</tr>
<tr>
<td>Pro</td>
<td>Tyr</td>
</tr>
<tr>
<td></td>
<td>100</td>
</tr>
<tr>
<td>Ala</td>
<td>Gly</td>
</tr>
<tr>
<td></td>
<td>115</td>
</tr>
<tr>
<td>Leu</td>
<td>Gly</td>
</tr>
<tr>
<td></td>
<td>130</td>
</tr>
<tr>
<td>Ala</td>
<td>Ala</td>
</tr>
<tr>
<td></td>
<td>140</td>
</tr>
<tr>
<td>Tyr</td>
<td>Glu</td>
</tr>
<tr>
<td></td>
<td>160</td>
</tr>
<tr>
<td>Gly</td>
<td>Aen</td>
</tr>
<tr>
<td></td>
<td>165</td>
</tr>
<tr>
<td>Residue</td>
<td>Sequence</td>
</tr>
<tr>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>105</td>
<td>His Gly</td>
</tr>
<tr>
<td>110</td>
<td>Ala Ala</td>
</tr>
<tr>
<td>115</td>
<td>Val Val</td>
</tr>
<tr>
<td>120</td>
<td>Ala Ala</td>
</tr>
<tr>
<td>125</td>
<td>Val Val</td>
</tr>
<tr>
<td>130</td>
<td>Ala Ala</td>
</tr>
<tr>
<td>135</td>
<td>Ser Ser</td>
</tr>
<tr>
<td>140</td>
<td>Tyr Asp</td>
</tr>
<tr>
<td>145</td>
<td>Ser Ser</td>
</tr>
<tr>
<td>150</td>
<td>Thr Thr</td>
</tr>
<tr>
<td>155</td>
<td>Leu Val</td>
</tr>
<tr>
<td>160</td>
<td>Thr Thr</td>
</tr>
<tr>
<td>165</td>
<td>Asp Gly</td>
</tr>
<tr>
<td>170</td>
<td>Tyr Trp</td>
</tr>
<tr>
<td>175</td>
<td>Asp Gly</td>
</tr>
<tr>
<td>180</td>
<td>His Gly</td>
</tr>
<tr>
<td>185</td>
<td>Ala Val</td>
</tr>
<tr>
<td>190</td>
<td>Ala Lys</td>
</tr>
<tr>
<td>195</td>
<td>Val Asp</td>
</tr>
<tr>
<td>200</td>
<td>Thr Lys</td>
</tr>
<tr>
<td>205</td>
<td>Ala Ala</td>
</tr>
</tbody>
</table>

**Continued from page 25**

<210> SEQ ID NO 6
<211> LENGTH: 245
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Engineered PLC

```
<400> SEQUENCE: 6
Trp Ser Ala Glu Asp Lys His Lys Gly Val Asn Ser His Leu Trp
1 5 10 15
Ile Val Asn Arg Ala Ile Asp Ile Met Ser Arg Asn Thr Thr Leu Val
20 25 30
Lys Asp Arg Val Ala Leu Leu Asp Glu Trp Arg Thr Glu Leu Glu
35 40 45
Asn Gly Ile Tyr Ala Ala Asp Tyr Glu Asn Pro Tyr Tyr Asp Asp Ser
50 55 60
Thr Phe Ala Ser His Phe Tyr Asp Pro Asp Asn Gly Lys Thr Tyr Ile
65 70 75 80
Pro Tyr Ala Lys Glu Ala Lys Glu Thr Gly Ala Lys Tyr Phe Lys Leu
90 95 95
Ala Gly Glu Ser Tyr Lys Asn Asp Met Lys Glu Ala Phe Phe Tyr
100 105 110
Leu Gly Leu Ser Leu His Tyr Leu Gly Asp Val Asn Glu Pro Met His
115 120 125
Ala Ala Ser Phe Thr Asp Leu Ser Tyr Pro Gin Gly Phe His Ser Lys
130 135 140
Tyr Glu Asn Phe Val Asp Thr Ile Lys Asp Asn Tyr Lys Val Thr Asp
145 150 155 160
Gly Asn Gly Tyr Trp Asn Trp Lys Gly Thr Asn Pro Glu Asp Trp Ile
165 170 175
His Gly Ala Ala Val Val Ala Lys Glu Asp Tyr Ala Gly Ile Val Asn
180 185 190
Asp Asn Thr Lys Asp Trp Phe Val Arg Ala Ala Val Ser Glu Glu Tyr
195 200 205
Ala Asp Lys Trp Arg Ala Glu Val Thr Pro Met Thr Gly Lys Arg Leu
210 215 220
Met Asp Ala Glu Arg Val Thr Ala Gly Tyr Ile Glu Leu Trp Phe Asp
225 230 235 240
Thr Tyr Gly Asn Arg
245
```
What is claimed is:
1. A composition comprising:
an isolated phospholipase C enzyme comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:1, wherein the amino acid residues at position 66 is a Trp (W) or a Tyr (Y); and
2. The composition of claim 1, wherein said vegetable oil is selected from the group consisting of soybean, rapeseed, sunflower seed, rice bran, sesame, palm or peanut oil.
3. The composition of claim 1, wherein the amino acid residues at positions 63, 131 and 134 of said isolated phospholipase C enzyme are not Asn (N).
4. The composition of claim 1, wherein the amino acid residues at positions 63, 131 and 134 of said isolated phospholipase C enzyme are independently selected from a Ser (S) and an Asp (D).
5. The composition of claim 4, wherein the amino acid residue at position 131 is an Asp (D), the amino acid residue at position 131 is a Ser (S), and the amino acid residue at position 134 is an Asp (D).
6. An isolated phospholipase C enzyme comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:1, wherein:
   the amino acid residue at position 66 is a Trp (W) or Tyr (Y); and
   the amino acid residues at positions 63, 131 and 134 are not Asn (N).
7. The isolated phospholipase C enzyme of claim 6, wherein the amino acid residues at positions 63, 131 and 134 are independently selected from a Ser (S) and an Asp (D).
8. The isolated phospholipase C enzyme of claim 6, wherein the amino acid residues at position 63 is an Asp (D), the amino acid residue at position 131 is a Ser (S) and the amino acid residue at position 134 is an Asp (D).
9. The isolated phospholipase C enzyme of claim 6, wherein said isolated polypeptide sequence comprises the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:5.
10. The composition of claim 3, wherein the amino acid residue at position 63 is an Asp (D), the amino acid residue at position 131 is a Ser (S), and the amino acid residue at position 134 is an Ala (A).
11. The composition of claim 1, wherein said isolated polypeptide sequence comprises the amino acid sequence of SEQ ID NO:3.
12. The composition of claim 1, wherein said isolated polypeptide sequence comprises the amino acid sequence of SEQ ID NO:5.
13. The isolated phospholipase C enzyme of claim 6, wherein the amino acid residue at position 63 is an Asp (D), the amino acid residue at position 131 is a Ser (S), and the amino acid residue at position 134 is an Ala (A).
14. The isolated phospholipase C enzyme of claim 6, wherein said isolated polypeptide sequence comprises the amino acid sequence of SEQ ID NO:3.
15. The isolated phospholipase C enzyme of claim 6, wherein said isolated polypeptide sequence comprises the amino acid sequence of SEQ ID NO:5.

* * * * *